Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Marketing applications for volanesorsen accepted in U.S., E.U. and Canada

Nov. 16, 2017

EMA committee supports approval of Endoceutics' Intrarosa

Nov. 15, 2017

Akcea initiates phase II program with AKCEA-ANGPTL3-LRx in rare hyperlipidemias

Nov. 14, 2017

EMA grants accelerated assessment to patisiran for hereditary ATTR amyloidosis

Nov. 14, 2017

EMA grants PRIME designation to Mereo's BPS-804

Nov. 13, 2017

vTv Therapeutics initiates simplici-T1 study of TTP-399 in type 1 diabetes

Nov. 10, 2017

ImmunoMolecular Therapeutics as new spinout of Barbara Davis Center for Diabetes

Nov. 10, 2017

Millendo Therapeutics reports topline phase II results on ATR-101, discontinues MLE-4901

Nov. 9, 2017

ApoGlyx divulges new AQP9 inhibitors

Nov. 9, 2017

Synlogic's SYNB-1020 demonstrates safety and tolerability in phase I study

Nov. 9, 2017

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...